Perceptions about the efficacy of extended half-life (EHL) factor products in persons with haemophilia (PWH): A national survey of haemophilia providers from haemophilia treatment centres (HTCs) in the United States.

Swaminathan, Neeraja; Salinas-Luna, Vanessa; Acharya, Suchitra; Sharathkumar, Anjali

Swaminathan, Neeraja; Salinas-Luna, Vanessa; Acharya, Suchitra; Sharathkumar, Anjali.

Afiliação

Swaminathan N; Division of Pediatric Hematology Oncology, Stead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.
Salinas-Luna V; Center for Inherited Blood Disorders, Orange, California, USA.
Acharya S; Division of Pediatric Hematology Oncology, Department of Pediatrics, Northwell Health, New Hyde Park, New York, USA.
Sharathkumar A; Division of Pediatric Hematology Oncology, Stead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.

Haemophilia ; 27(6): e780-e783, 2021 Nov.

Article em En | MEDLINE | ID: mdl-34592042

Assuntos

Hemofilia A; Hemofilia B; Fator VIII/uso terapêutico; Meia-Vida; Hemofilia A/tratamento farmacológico; Humanos; Estados Unidos

Palavras-chave

extended half-life factor concentrates (EHLs); factor switching; haemophilia; standard half-life factor concentrates (SHLs)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hemofilia B / Hemofilia A Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hemofilia B / Hemofilia A Idioma: En Ano de publicação: 2021 Tipo de documento: Article